Demographic and baseline characteristics of ENKTL patients in 4 cohorts
| Variables . | Training cohort (n = 336) . | Internal validation cohort (n = 144) . | External validation cohort 1 (n = 142) . | External validation cohort 2 (n = 100) . |
|---|---|---|---|---|
| Age, y | ||||
| ≤60 | 286 (85) | 124 (86) | 111 (78) | 67 (67) |
| >60 | 50 (15) | 20 (14) | 31 (22) | 33 (33) |
| Sex | ||||
| Male | 223 (66) | 102 (71) | 98 (69) | 75 (75) |
| Female | 113 (34) | 42 (29) | 44 (31) | 25 (25) |
| B symptoms | ||||
| No | 191 (57) | 78 (54) | 81 (57) | 54 (54) |
| Yes | 145 (43) | 66 (46) | 61 (43) | 46 (46) |
| ECOG-PS | ||||
| 0-1 | 307 (91) | 130 (90) | 130 (92) | 75 (75) |
| ≥2 | 29 (9) | 14 (10) | 12 (8) | 25 (25) |
| Ann Arbor stage | ||||
| I-II | 261 (78) | 112 (78) | 100 (70) | 54 (54) |
| III-IV | 75 (22) | 32 (22) | 42 (30) | 46 (46) |
| Lymph node involvement | ||||
| No | 161 (48) | 68 (47) | 61 (43) | 41 (41) |
| Regional | 133 (40) | 56 (39) | 40 (28) | 37 (37) |
| Distant | 42 (12) | 20 (14) | 41 (29) | 22 (22) |
| Nonnasal type | ||||
| Yes | 54 (17) | 30 (21) | 15 (11) | 12 (12) |
| No | 282 (83) | 114 (79) | 127 (89) | 88 (88) |
| No. of extranodal involvement | ||||
| 0 or 1 | 197 (59) | 101 (70) | 80 (56) | 57 (57) |
| ≥2 | 139 (41) | 43 (30) | 62 (44) | 43 (43) |
| LDH | ||||
| Normal | 203 (60) | 83 (58) | 81 (57) | 39 (39) |
| Elevated | 133 (40) | 61 (42) | 61 (43) | 61 (61) |
| IPI | ||||
| 0-1 | 256 (76) | 97 (68) | 77 (54) | 44 (44) |
| 2 | 57 (17) | 34 (23) | 34 (24) | 14 (14) |
| 3 | 21 (6) | 12 (8) | 21 (15) | 19 (19) |
| 4-5 | 2 (1) | 1 (1) | 10 (7) | 23 (23) |
| KPI | ||||
| Group 1 | 42 (13) | 20 (14) | 19 (13) | 12 (12) |
| Group 2 | 129 (38) | 43 (30) | 54 (38) | 19 (19) |
| Group 3 | 108 (32) | 55 (38) | 25 (18) | 33 (33) |
| Group 4 | 57 (17) | 26 (18) | 44 (31) | 36 (36) |
| PINK | ||||
| Low risk | 171 (51) | 64 (44) | 60 (42) | 33 (33) |
| Intermediate risk | 120 (36) | 61 (43) | 48 (34) | 36 (36) |
| High risk | 45 (13) | 19 (13) | 34 (24) | 31 (31) |
| Variables . | Training cohort (n = 336) . | Internal validation cohort (n = 144) . | External validation cohort 1 (n = 142) . | External validation cohort 2 (n = 100) . |
|---|---|---|---|---|
| Age, y | ||||
| ≤60 | 286 (85) | 124 (86) | 111 (78) | 67 (67) |
| >60 | 50 (15) | 20 (14) | 31 (22) | 33 (33) |
| Sex | ||||
| Male | 223 (66) | 102 (71) | 98 (69) | 75 (75) |
| Female | 113 (34) | 42 (29) | 44 (31) | 25 (25) |
| B symptoms | ||||
| No | 191 (57) | 78 (54) | 81 (57) | 54 (54) |
| Yes | 145 (43) | 66 (46) | 61 (43) | 46 (46) |
| ECOG-PS | ||||
| 0-1 | 307 (91) | 130 (90) | 130 (92) | 75 (75) |
| ≥2 | 29 (9) | 14 (10) | 12 (8) | 25 (25) |
| Ann Arbor stage | ||||
| I-II | 261 (78) | 112 (78) | 100 (70) | 54 (54) |
| III-IV | 75 (22) | 32 (22) | 42 (30) | 46 (46) |
| Lymph node involvement | ||||
| No | 161 (48) | 68 (47) | 61 (43) | 41 (41) |
| Regional | 133 (40) | 56 (39) | 40 (28) | 37 (37) |
| Distant | 42 (12) | 20 (14) | 41 (29) | 22 (22) |
| Nonnasal type | ||||
| Yes | 54 (17) | 30 (21) | 15 (11) | 12 (12) |
| No | 282 (83) | 114 (79) | 127 (89) | 88 (88) |
| No. of extranodal involvement | ||||
| 0 or 1 | 197 (59) | 101 (70) | 80 (56) | 57 (57) |
| ≥2 | 139 (41) | 43 (30) | 62 (44) | 43 (43) |
| LDH | ||||
| Normal | 203 (60) | 83 (58) | 81 (57) | 39 (39) |
| Elevated | 133 (40) | 61 (42) | 61 (43) | 61 (61) |
| IPI | ||||
| 0-1 | 256 (76) | 97 (68) | 77 (54) | 44 (44) |
| 2 | 57 (17) | 34 (23) | 34 (24) | 14 (14) |
| 3 | 21 (6) | 12 (8) | 21 (15) | 19 (19) |
| 4-5 | 2 (1) | 1 (1) | 10 (7) | 23 (23) |
| KPI | ||||
| Group 1 | 42 (13) | 20 (14) | 19 (13) | 12 (12) |
| Group 2 | 129 (38) | 43 (30) | 54 (38) | 19 (19) |
| Group 3 | 108 (32) | 55 (38) | 25 (18) | 33 (33) |
| Group 4 | 57 (17) | 26 (18) | 44 (31) | 36 (36) |
| PINK | ||||
| Low risk | 171 (51) | 64 (44) | 60 (42) | 33 (33) |
| Intermediate risk | 120 (36) | 61 (43) | 48 (34) | 36 (36) |
| High risk | 45 (13) | 19 (13) | 34 (24) | 31 (31) |
All data are n (%).